Creative Commons source reading · Stroke recovery and rehabilitation
Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.
Natan M Bornstein; Alla Guekht; Johannes Vester; Wolf-Dieter Heiss; Eugene Gusev; Volker Hömberg; Volker W Rahlfs; Ovidiu Bajenaru; Bogdan O Popescu; Dafin Muresanu
Originally published in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017-12-16
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
This meta-analysis combines the results of nine ischemic stroke trials, assessing efficacy of Cerebrolysin on global neurological improvement during early post-stroke period. Cerebrolysin is a parenterally administered neuropeptide preparation approved for treatment of stroke. All included studies had a prospective, randomized, double-blind, placebo-controlled design. The patients were treated with 30-50 ml Cerebrolysin once daily for 10-21 days, with treatment initiation within 72 h after onset of ischemic stroke. For five studies, original analysis data were available for meta-analysis (individual patient data analysis); for four studies, aggregate data were used. The combination by meta-analytic procedures was pre-planned and the methods of synthesis were pre-defined under blinded conditions. Search deadline for the present meta-analysis was December 31, 2016.
Discussion
Our meta-analysis comprised a total of 1879 patients and showed the superiority of Cerebrolysin compared to placebo on both neurological deficits, measured by NIHSS, and functional outcome, measured by mRS.
Conclusions
Our meta-analysis confirms previous evidence that Cerebrolysin has a beneficial effect on early global neurological deficits in patients with acute ischemic stroke. Moreover, our results showed a clinically relevant and significant improvement of functional outcome at day 90 based on the mRS in the moderate to severe group.
Editorial reading guide
- How did the authors define recovery, and when did they measure it?
- Does the outcome reflect a laboratory measure, a functional change or participation in daily life?
